A tale of two centrifugal left ventricular assist devices

Jacob N. Schroder, MD, and Carmelo A. Milano, MD

For almost a decade, the HeartMate II device (Abbott, Chicago, Ill) has been the most commonly installed durable left ventricular assist device (LVAD) in the United States, both as a bridge to transplant and for destination indications. This pump uses an Archimedes screw design with a resultant axial blood flow pattern; a single, central ruby bearing supports the rotor. Most recently, two publications have reported prospective, randomized trials in which the HeartMate II LVAD was compared with novel pumps that are smaller and use a centrifugal blood flow pattern, the HeartWare LVAD (HVAD; Medtronic, Minneapolis, Minn) and the HeartMate III (Abbott) LVAD1-2 (Figure 1). Although positive results with the HeartMate II device were responsible for the expansion of destination therapy, reports within the last 5 years have described the important issue of pump thrombosis, which frequently requires reoperation for device replacement.3,4 The rate of pump thrombosis with need for device replacement was reported as high as 10% during the first year after implantation.5 In addition, power cord wear and failure with the HeartMate II device was identified as another cause for pump stoppage and need for replacement. An important objective for these newer devices was therefore improvement in adverse event profiles relative to the HeartMate II, and reduction of pump thrombosis in particular.

The ENDURANCE trial (A Clinical Trial to Evaluate the HeartWare Ventricular Assist System) randomly allocated patients who were older and deemed ineligible for transplant to receive either the HVAD or the HeartMate II LVAD (2:1 randomization).1 The HVAD is a considerably smaller centrifugal pump with a magnetically levitated rotor; the pump is positioned entirely within the pericardium. The HVAD is already approved by the Food and Drug Administration for bridge to transplant indications, and the ENDURANCE trial sought to examine its performance during more chronic support as destination therapy. The primary end point was a composite consisting of survival free from disabling stroke or need for device replacement at 2 years. Therapy with the HVAD was equivalent to that with the HeartMate II with regard to achieving this primary end point (55.4% vs 59.1% success, respectively). Furthermore, overall survival and freedom from disabling stroke were equivalent for the groups, and the HVAD group had fewer device failures relative to HeartMate II, mainly as a result of less pump thrombosis necessitating replacement in the HVAD group. Unfortunately, the benefit of reduced pump thrombosis for the HVAD was nullified by an increased overall stroke rate, which was roughly 3 times greater for the HVAD versus the HeartMate II (0.29 events/patient-y of support vs 0.09 events/patient-y of support, respectively). An increased stroke rate was previously reported in the ADVANCE bridge to transplant (Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure) trial, but this became more apparent in the ENDURANCE trial, probably because older patients were examined for a longer period of follow-up.1,5 Retrospective analyses of the ENDURANCE and ADVANCE data have shown an important association between hypertension during HVAD support and increased incidence of stroke. This has led to the ENDURANCE supplemental trial, in which destination-therapy patients are again randomly allocated to HVAD versus HeartMate II, but those with HVAD placement are managed with increased blood pressure monitoring and a goal mean arterial blood pressure below 90 mm Hg. In this trial, patients were discharged with special equipment to monitor blood pressure, and they were required to maintain a log of daily measurements. The primary end point for this trial is neurological injury at 1 year, and the results should be submitted for publication this year. In addition,
The HeartMate III is also a blood pump with a centrifugal design and a completely magnetically levitated rotor. Like the HVAD pump, the HeartMate III has no bearings, which should achieve enhanced durability. Other important, unique design features for the HeartMate III include increased gaps (distances between the rotor and housing) and an algorithm for pump speed changes every 2 seconds to enhance washing of the pump. Finally, a modular power cord design facilitates cord replacement. Importantly, this report describes results from a short-term cohort followed up for only 6 months that included patients for whom the intention was destination or bridge to transplant. This report reviews outcomes from a very small subset of the entire trial (the larger trial includes 1000 patients who will be followed up for 2 years). The current report therefore represents a limited and early snapshot of the HeartMate III’s clinical performance, and it is therefore premature to draw comparisons with the HVAD trial (ENDURANCE) in which an older cohort was followed for a substantially longer period.

The primary end point for MOMENTUM 3 is the same composite used in the ENDURANCE trial (freedom from death and disabling stroke on the original device). Patients treated with the HeartMate III LVAD more commonly achieved the primary end point than did those who received the HeartMate II at the 6-month end point (86.2% vs 76.8%, respectively; \( P = .037 \)). The mortality and rate of disabling stroke were similar for the groups, but there was a substantial reduction in the need for device replacement for the group who received the HeartMate III. In fact, there were no pump thromboses requiring replacement for the HeartMate III, whereas the HeartMate II continued to display a disturbing rate of replacement for pump thrombosis (11 replacements in 142 cases during the 6-month follow up). This would suggest that the new design features may have resulted in improved washing of the HeartMate III pump, preventing clot formation or deposition and subsequent hemolysis. Importantly, other adverse events, such as overall stroke and bleeding events, were similar between the groups (Table 1).

Although this MOMENTUM 3 cohort has only been followed up for a short duration (6 months), the problem of pump thrombosis appears to be positively affected. If so, this is an important milestone, because this event has been shown to affect morbidity, rehospitalization, and mortality. Furthermore, many speculate that pump thrombosis rates

### TABLE 1. Rate of adverse events during 6-month follow-up in the MOMENTUM 3 trial

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>HeartMate III</th>
<th>HeartMate II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke</td>
<td>7.9%</td>
<td>10.9%</td>
</tr>
<tr>
<td>Bleeding</td>
<td>33.1%</td>
<td>39%</td>
</tr>
<tr>
<td>Suspected pump thrombosis</td>
<td>0%</td>
<td>10.1%</td>
</tr>
</tbody>
</table>

Data represent percentage of cohort with adverse events. Adapted from Mehra and colleagues.
with the Heartmate II device prevented the launch of the REVIVE-IT (Randomized Evaluation of VAD Intervention before Inotropic Therapy) trial to examine outcomes from LVAD support for a less sick cohort of patients with heart failure. In other words, the rates of device-related adverse events with the HeartMate II prevented its application to less sick patients who were not at high risk for death from heart failure. LVAD therapy in general will be advanced if the issue of pump thrombosis is truly eliminated with this newer design. More generally, it is encouraging that device design focused on this specific adverse event appears to have had a positive effect on clinical outcomes, giving hope that other difficult complications, such as device-specific infection, bleeding events, and stroke, can be overcome with design change.

Another important and more general observation from these trials relates to the rate of enrollment and the time required to complete enrollment. For both these trials, a large number of patients were enrolled and randomly allocated in a relatively short period (MOMENTUM 3, n = 1028 patients; ENDURANCE, n = 445 patients). This represents a considerable change relative to earlier device trials, such as the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial or even the HeartMate II destination trial, which enrolled patients much more slowly. The rapid completion of enrollment for these trials results from the overall increased clinical application of the technology, effective trial design, and an engaged research community (Figure 2). The rapid enrollment portends well for the future investigation of newer LVAD designs, testing of modification of existing devices, or trials of novel LVAD management strategies. The faster that we can test and answer questions in this field, the more effective the therapy will be for patients with advanced heart failure.

Conflict of Interest Statement
C.A.M. is a consultant and educator for Medtronic, Minneapolis, Minn, and for Abbott, Chicago, Ill. J.N.S. has nothing to disclose with regard to commercial support.

References